Cargando…

Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti

BACKGROUND: Recently, the discovery of the elansolids, a group of macrolides, was reported. The molecules show activity against methicillin-resistant Staphylococcus aureus as well as other gram-positive organisms. This fact renders those substances a promising starting point for future chemical deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Beckmann, Amelie, Hüttel, Stephan, Schmitt, Viktoria, Müller, Rolf, Stadler, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561589/
https://www.ncbi.nlm.nih.gov/pubmed/28818083
http://dx.doi.org/10.1186/s12934-017-0756-z
_version_ 1783257857269956608
author Beckmann, Amelie
Hüttel, Stephan
Schmitt, Viktoria
Müller, Rolf
Stadler, Marc
author_facet Beckmann, Amelie
Hüttel, Stephan
Schmitt, Viktoria
Müller, Rolf
Stadler, Marc
author_sort Beckmann, Amelie
collection PubMed
description BACKGROUND: Recently, the discovery of the elansolids, a group of macrolides, was reported. The molecules show activity against methicillin-resistant Staphylococcus aureus as well as other gram-positive organisms. This fact renders those substances a promising starting point for future chemical development. The active atropisomers A1/A2 are formed by macrolactonization of the biosynthesis product A3 but are prone to ring opening and subsequent formation of several unwanted side products. Recently it could be shown that addition of different nucleophiles to culture extracts of Chitinophaga sancti enable the formation of new stable elansolid derivatives. Furthermore, addition of such a nucleophile directly into the culture led exclusively to formation of a single active elansolid derivative. Due to low product yields, methods for production of gram amounts of these molecules have to be established to enable further development of this promising compound class. RESULTS: Production of elansolid A2 by C. sancti was enabled using a synthetic medium with sucrose as carbon source to a final concentration of 18.9 mg L(−1). A fed-batch fermentation was ensued that resulted in an elansolid A2 concentration of 55.3 mg L(−1). When using glucose as carbon source in a fed-batch fermentation only 34.4 mg L(−1) elansolid A2 but 223.1 mg L(−1) elansolid C1 were produced. This finding was not unexpected since elansolids A1/A2 and A3 have been reported to easily react with nucleophiles like anthranilic acid, a precursor of tryptophan biosynthesis. Due to the fact that nucleophiles can be incorporated in vivo, a fed-batch cultivation under identical conditions, with addition of anthranilic acid was carried out and lead to almost exclusive formation of elansolid C1 (257.5 mg L(−1)). CONCLUSION: Reproducible elansolid A2 and C1 production is feasible in different synthetic media at relatively high concentrations that will allow further investigation and semi-synthetic optimization. The feeding of anthranilic acid enables the exclusive production of the stable elansolid derivative C1, which reduces product loss by unspecific reactions and eases downstream processing. This derivative shows activity in the same range as the elansolids A1/A2. Hence, the method can possibly serve as a model-process for incorporation of other nucleophiles and biotechnological production of specifically designed molecules.
format Online
Article
Text
id pubmed-5561589
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55615892017-08-18 Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti Beckmann, Amelie Hüttel, Stephan Schmitt, Viktoria Müller, Rolf Stadler, Marc Microb Cell Fact Research BACKGROUND: Recently, the discovery of the elansolids, a group of macrolides, was reported. The molecules show activity against methicillin-resistant Staphylococcus aureus as well as other gram-positive organisms. This fact renders those substances a promising starting point for future chemical development. The active atropisomers A1/A2 are formed by macrolactonization of the biosynthesis product A3 but are prone to ring opening and subsequent formation of several unwanted side products. Recently it could be shown that addition of different nucleophiles to culture extracts of Chitinophaga sancti enable the formation of new stable elansolid derivatives. Furthermore, addition of such a nucleophile directly into the culture led exclusively to formation of a single active elansolid derivative. Due to low product yields, methods for production of gram amounts of these molecules have to be established to enable further development of this promising compound class. RESULTS: Production of elansolid A2 by C. sancti was enabled using a synthetic medium with sucrose as carbon source to a final concentration of 18.9 mg L(−1). A fed-batch fermentation was ensued that resulted in an elansolid A2 concentration of 55.3 mg L(−1). When using glucose as carbon source in a fed-batch fermentation only 34.4 mg L(−1) elansolid A2 but 223.1 mg L(−1) elansolid C1 were produced. This finding was not unexpected since elansolids A1/A2 and A3 have been reported to easily react with nucleophiles like anthranilic acid, a precursor of tryptophan biosynthesis. Due to the fact that nucleophiles can be incorporated in vivo, a fed-batch cultivation under identical conditions, with addition of anthranilic acid was carried out and lead to almost exclusive formation of elansolid C1 (257.5 mg L(−1)). CONCLUSION: Reproducible elansolid A2 and C1 production is feasible in different synthetic media at relatively high concentrations that will allow further investigation and semi-synthetic optimization. The feeding of anthranilic acid enables the exclusive production of the stable elansolid derivative C1, which reduces product loss by unspecific reactions and eases downstream processing. This derivative shows activity in the same range as the elansolids A1/A2. Hence, the method can possibly serve as a model-process for incorporation of other nucleophiles and biotechnological production of specifically designed molecules. BioMed Central 2017-08-17 /pmc/articles/PMC5561589/ /pubmed/28818083 http://dx.doi.org/10.1186/s12934-017-0756-z Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Beckmann, Amelie
Hüttel, Stephan
Schmitt, Viktoria
Müller, Rolf
Stadler, Marc
Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti
title Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti
title_full Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti
title_fullStr Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti
title_full_unstemmed Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti
title_short Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti
title_sort optimization of the biotechnological production of a novel class of anti-mrsa antibiotics from chitinophaga sancti
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561589/
https://www.ncbi.nlm.nih.gov/pubmed/28818083
http://dx.doi.org/10.1186/s12934-017-0756-z
work_keys_str_mv AT beckmannamelie optimizationofthebiotechnologicalproductionofanovelclassofantimrsaantibioticsfromchitinophagasancti
AT huttelstephan optimizationofthebiotechnologicalproductionofanovelclassofantimrsaantibioticsfromchitinophagasancti
AT schmittviktoria optimizationofthebiotechnologicalproductionofanovelclassofantimrsaantibioticsfromchitinophagasancti
AT mullerrolf optimizationofthebiotechnologicalproductionofanovelclassofantimrsaantibioticsfromchitinophagasancti
AT stadlermarc optimizationofthebiotechnologicalproductionofanovelclassofantimrsaantibioticsfromchitinophagasancti